The molecular biology and therapeutic potential of Nrf2 in leukemiaAtefeh Khodakarami, Farhad Jadidi-Niaragh, Sara Adibfar et al.|Cancer Cell International|2022Cited by 46
The sensitivity of acute myeloid leukemia cells to cytarabine is increased by suppressing the expression of Heme oxygenase-1 and hypoxia-inducible factor 1-alphaMohammad Reza Sadeghi, Farhad Jadidi‐Niaragh, Asma Moslehi et al.|Cancer Cell International|2024Cited by 20
The prognostic and therapeutic potentials of CTLA-4 in hematological malignanciesMohammad Reza Sadeghi, Farhad Jadidi-Niaragh, Atefeh Khodakarami et al.|Expert Opinion on Therapeutic Targets|2022Cited by 16
Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to CyclophosphamideAtefeh Khodakarami, Farhad Jadidi‐Niaragh, Mahsa Afsari Kashani et al.|Cell Communication and Signaling|2023Cited by 16
The role of <scp>SF3B1</scp> and <scp>NOTCH1</scp> in the pathogenesis of leukemiaShiva Abolhasani, Farhad Jadidi‐Niaragh, Seyyed Sina Hejazian et al.|IUBMB Life|2022Cited by 7